Jose Manuel Otero, an officer of Lexeo Therapeutics, Inc., filed a Form 144 notice of proposed sale of securities with the SEC on November 17, 2026, covering 1,285 shares of common stock acquired through restricted stock vesting.
Key Highlights
- Proposed seller: Jose Manuel Otero, identified in the filing as an officer of Lexeo Therapeutics, Inc.
- Shares proposed for sale: 1,285 shares of common stock, with an aggregate market value of $4,192.19.
- Acquisition date and method: The 1,285 shares were acquired on November 16, 2026, via restricted stock vesting from the issuer, with payment classified as compensation.
- Approximate sale date: November 17, 2026, through Fidelity Brokerage Services LLC.
- Shares outstanding: 82,788,599 shares of common stock outstanding at the time of filing, according to the notice.
- Prior sales: On August 18, 2026, Otero sold 1,304 shares of common stock for gross proceeds of $6,464.05, as disclosed in the past three months' sales section.
- Purpose noted: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
Lexeo Therapeutics Officer Files Form 144 for Post-Vesting Share Sale
According to the Form 144 notice, Jose Manuel Otero, an officer at Lexeo Therapeutics, Inc. (NASDAQ:LXEO), proposed the sale of 1,285 shares of the company's common stock. The filing was submitted on November 17, 2026, with an approximate sale date of the same day, executed through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.
The shares proposed for sale were acquired on November 16, 2026, through a restricted stock vesting transaction from the issuer, described in the filing as compensation. The aggregate market value of the proposed sale is listed as $4,192.19. The filing includes a remark stating that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," which the filing presents as the stated context for the transaction.
The notice also discloses that, within the prior three months, Otero sold 1,304 shares of Lexeo Therapeutics common stock on August 18, 2026, generating gross proceeds of $6,464.05. At the time of the current filing, Lexeo Therapeutics reported 82,788,599 total shares of common stock outstanding. The Form 144 was signed by Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jose M. Otero.
What Was Disclosed
Lexeo Therapeutics officer Jose Manuel Otero filed a Form 144 on November 17, 2026, proposing the sale of 1,285 shares of common stock, valued at $4,192.19, acquired via restricted stock vesting the prior day, with the sale attributed to covering tax obligations from an equity award settlement.



Please wait processing your request...